Ultima Comunicazione - inviata da: Neuroitc - Martedì, 19 Febbraio 2008 09:19
Ci scusiamo se le nostre risposte non possono essere sempre tempestive o se non viene fornita una risposta a tutti quanti ma tutto è in funzione dei nostri impegni personali e disponibilità che non possono essere sempre costanti. Grazie
Area Articoli

Area Articoli->Sclerosi Multipla (SM)->Linee Guida per analisi del liquido cerebrospinale [ Cerca ]

Linee Guida per analisi del liquido cerebrospinale
Titolo Linee Guida per analisi del liquido cerebrospinale
Descrizione © Archives of Neurology - (2005;62:865-870)
Inviata da Neuroitc
La diagnosi di sclerosi multipla e' basata su criteri clinici supportati da esami strumentali quali Risonanza Magnetica, Potenziali Evocati (specialmente i visivi) e Analisi del Liquor. Qui sotto riportiamo le linee guida. Per un documento piu' completo, comprensivo di iter passo passo per la diagnosi, vi rimando alla sezione Download

Magnetic resonance imaging (MRI) Three out of four:
1 Gd-enhancing or 9 T2 hyperintense lesions if no Gd-enhancing lesion
1 or more infratentorial lesions
1 or more juxtacortical lesions
3 or more periventricular lesions
(1 spinal cord lesion = 1 brain lesion)

Cerebrospinal fluid (CSF)
Oligoclonal IgG bands in CSF (and not serum)
or elevated IgG index

Evoked potentials (EP)
Delayed but well-preserved wave form

MRI Evidence of Dissemination in Time
A Gd-enhancing lesion demonstrated in a scan done at least 3 months following onset of clinical attack at a site different from attack,

or

In absence of Gd-enhancing lesions at 3 month scan, follow-up scan after an additional 3 months showing Gd-lesion or new T2 lesion.



Un gruppo di studio di esperti in SM ha redatto alcune linee guida aggiuntive per l'analisi del liquido cerebrospinale (CSF) che vanno ad integrare i precedenti criteri diagnostici internazionali al fine di aumentare la specificita' della diagnosi e ridurre il numero di errate diagnosi.

Riportiamo qui sotto i 12 criteri elaborati dal gruppo di studio:

1. A qualitative assessment of CSF for IgG is the single most informative analysis, and the U.S. Food and Drug Administration agrees that this technique should be designated as the gold standard. This is best performed using IEF together with some form of immunodetection (blotting or fixation).

2. This qualitative analysis should be performed on unconcentrated CSF and must be compared directly with a serum sample run simultaneously in the same assay in an adjacent track.

3. For optimal results, runs should use similar amounts of IgG from paired serum sample and CSF.

4. Each set of samples should be run with recognized positive and negative controls. The entire gel should be rejected if oligoclonal bands in the positive controls are poorly developed or the negative controls are overdeveloped.

5. CSF reports of qualitative analysis should be made in terms of one of the five recognized staining patterns of oligoclonal banding.

6. An individual experienced in the technique used should interpret the results.

7. Neurologists should consider the results of all other tests performed as part of the CSF panel, including white blood cell count and levels of protein, glucose, and lactate.

8. Evaluation using light chains for immunodetection may be helpful in certain cases to resolve equivocal oligoclonal IgG patterns.

9. If clinical suspicion is high but results of CSF testing are equivocal, negative, or show only a single band, neurologists should consider repeating the lumbar puncture and CSF analysis.

10. Quantitative IgG analysis is an informative complementary test. However, it is not considered a substitute for qualitative IgG assessment, which has the highest sensitivity and specificity.

11. When CSF testing is performed, nonlinear formulas should be used to measure intrathecal IgG levels that consider the integrity of the blood–CSF barrier ( BCB ) by also measuring the ratio of albumin in CSF to serum (also known as Qalb, a measure of BCB "leakiness").

12. Laboratories performing routine CSF analysis should ensure their own internal quality control and should participate in external quality assessment controls. This should allow laboratories to maintain a high standard of reliability and performance, as has been recommended in some international consensus papers.


Annals of Neurology
Volume 50, Issue 1, 2001. Pages 121-127
Copyright © 2001 Wiley-Liss, Inc.

© Archives of Neurology - (2005;62:865-870)
Giudizio Voti: 2 - Media: 5

Inserisci un commento Vota
Commenti
Neuroitc
30 Nov 2005
Nella sezione download è presente il PDF sulle Linee Guida Globali.
Neuroitc
23 Nov 2005
Seguirà versione italiana tradotta

Statistiche
Abbiamo 4 articoli nel nostro database
Il più visto: Farmaci impiegati nel trattamento della Sclerosi Multipla
Il più votato: Azatriopina: riduzione nuove lesioni infiammatorie

Utenti totali presenti nella sezione Articoli: 4 (0 Utenti Registrati 4 Visitatori e 0 Utenti Anonimi)
Gli utenti visibili sono: 0


MKPReviews ©2004-2005 All rights reserved
 


MKPortal M1.1 ©2003-2006 All rights reserved
Pagina generata in 0.09645 secondi con 20 query